Investigator-initiated Studies (IIS) are an integral part of the investigational drug development process and are increasing gradually, year on year, on a global scale. Victoria Maguire of Almac discusses that to keep patients, their safety and experience at the heart of IIS trials, investigators need to define the IMP supply strategy at the earliest opportunity.